Takeda To Ditch Orexigen In Another Deal Exit?
This article was originally published in PharmAsia News
It's starting to look like there may be an acrimonious divorce in store for Orexigen and its marketing partner Takeda, now that the Japanese pharma has said it won't pay for another costly cardiovascular outcomes study for their obesity drug Contrave after the first was halted.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.